MedTrace Logo

Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck

NCT00570674 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2017-11-13

Study results available
· View outcomes & findings →

Summary

The purpose of the Phase I part of this research study is to determine the safest and most effective dose of Abraxane when given in combination with carboplatin and Erbitux during radiation therapy for head and neck cancer. The purpose of the Phase II part of this study is to determine the effects of the treatment on head and neck cancers, as well as to further study the safety of this treatment.

Conditions

  • Squamous Cell Carcinoma of the Head and Neck
  • Basaloid Squamous Cell Carcinoma
  • Undifferentiated Carcinoma
  • Adenosquamous Cell Carcinoma

Interventions

DRUG

Abraxane

DRUG

Erbitux

DRUG

Carboplatin

RADIATION

Intensity Modulated Radiation Therapy

Sponsors & Collaborators

Principal Investigators

  • Roy B. Tishler, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2013-10-31
Completion
2013-10-31

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00570674 on ClinicalTrials.gov